Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 47,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
142% more first-time investments, than exits
New positions opened: 475 | Existing positions closed: 196
6% more funds holding
Funds holding: 3,608 [Q3] → 3,816 (+208) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 1,506 | Existing positions reduced: 1,451
0.14% more ownership
Funds ownership: 81.8% [Q3] → 81.94% (+0.14%) [Q4]
9% less call options, than puts
Call options by funds: $9.28B | Put options by funds: $10.1B
11% less capital invested
Capital invested by funds: $676B [Q3] → $604B (-$72.2B) [Q4]
30% less funds holding in top 10
Funds holding in top 10: 463 [Q3] → 325 (-138) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$700
22%
downside
Avg. target
$965
7%
upside
High target
$1,124
25%
upside
7 analyst ratings
6 positive
86%
0 neutral
0%
1 negative
14%
HSBC Rajesh Kumar 50% 1-year accuracy 2 / 4 met price target | 22%downside $700 | Reduce Downgraded | 28 Apr 2025 |
Cantor Fitzgerald Carter Gould 39% 1-year accuracy 12 / 31 met price target | 8%upside $975 | Overweight Initiated | 22 Apr 2025 |
Guggenheim Seamus Fernandez 43% 1-year accuracy 9 / 21 met price target | 3%upside $928 | Buy Maintained | 14 Apr 2025 |
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target | 25%upside $1,124 | Overweight Maintained | 9 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 1%downside $888 | Buy Upgraded | 8 Apr 2025 |
Financial journalist opinion
Based on 136 articles about LLY published over the past 30 days
Positive
CNBC
5 hours ago
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Neutral
Benzinga
7 hours ago
Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?
Eli Lilly And Co LLY will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours.
Positive
The Motley Fool
15 hours ago
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion.
Positive
Seeking Alpha
1 day ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Neutral
Business Wire
1 day ago
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
SAN DIEGO--(BUSINESS WIRE)-- #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly's named targets on time.
Positive
Seeking Alpha
2 days ago
Eli Lilly: Why Orforglipron Matters, A Lot
Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to injectable semaglutide. The importance of these LLY results cannot be understated, as this should be the first oral obesity product that can be produced at scale to satisfy global demand.
Neutral
CNBC Television
2 days ago
Calls of the Day: Eli Lilly
Which stock rocked the table with a double downgrade? The Investment Committee reveals today's Calls of the Day!
Positive
Zacks Investment Research
2 days ago
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Negative
Barrons
2 days ago
Eli Lilly Stock Just Got Its First Bear. Where Weight-Loss Drugs Go From Here.
HSBC double downgraded Eli Lilly to Reduce, citing too much optimism around its new weight-loss pill, and the strength of Novo Nordisk's Ozempic brand.
Positive
Zacks Investment Research
2 days ago
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Charts implemented using Lightweight Charts™